Tissue factor is the receptor for plasminogen type 1 on 1-LN human prostate cancer cells

Blood. 2002 Jun 15;99(12):4562-7. doi: 10.1182/blood.v99.12.4562.

Abstract

Tissue factor (TF), the initiator of the extrinsic pathway of coagulation, binds plasminogen (Pg) with high affinity through an interaction between kringles 1-3 of Pg and the extracellular domain of TF. We investigated the binding of Pg type 1 (Pg 1) and Pg type 2 (Pg 2) to highly invasive, TF-expressing, 1-LN human prostate tumor cells and to TF isolated from 1-LN cell membranes. Pg 1, containing both N-linked and O-linked oligosaccharide chains, bound to isolated TF with high affinity, whereas Pg 2, containing only one O-linked oligosaccharide chain, did not bind to TF. Although Pg 1 and Pg 2 bind to 1-LN cells, only anti-TF antibodies inhibited the binding of Pg 1, suggesting that TF functions as the receptor for Pg 1 on 1-LN cells. Binding of Pg 1 to isolated TF was inhibited by 6-aminohexanoic acid and alpha-methylmannoside, suggesting that Pg 1 L-lysine binding sites and the biantennary, mannose-containing N-linked oligosaccharide chain are involved in this interaction. Binding of Pg 1 to 1-LN cells promoted activation by receptor-bound urinary-type Pg activator (u-PA) and initiated a Ca(++) signaling cascade. In previous studies we demonstrated that the Pg 2 O-linked carbohydrate chain is essential for its binding to CD26 on 1-LN cells. The current studies suggest that Pg oligosaccharide chains regulate the binding of Pg 1 and Pg 2 to separate receptors on the cell surface.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Binding Sites
  • Calcium Signaling / drug effects
  • Glycosylation
  • Humans
  • Male
  • Matrix Metalloproteinase 9 / drug effects
  • Neoplasm Invasiveness
  • Oligosaccharides
  • Plasminogen / chemistry
  • Plasminogen / metabolism
  • Plasminogen / pharmacology*
  • Prostatic Neoplasms / metabolism
  • Prostatic Neoplasms / pathology*
  • Protein Binding
  • Protein Processing, Post-Translational
  • Thromboplastin / metabolism*
  • Tumor Cells, Cultured
  • Urokinase-Type Plasminogen Activator / pharmacology

Substances

  • Oligosaccharides
  • Plasminogen
  • Thromboplastin
  • Urokinase-Type Plasminogen Activator
  • Matrix Metalloproteinase 9